Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on September 28, 2005
Journal of the American Society of Nephrology
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2005030321
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2005030321v1
16/11/3371    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greene, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greene, T.


CLINICAL SCIENCE: Clinical Nephrology

Association of Achieved Dialysis Dose with Mortality in the Hemodialysis Study: An Example of "Dose-Targeting Bias"

Tom Greene 1*, John Daugirdas 1, Thomas Depner 1, Michael Allon 1, Gerald Beck 1, Cameron Chumlea 1, James Delmez 1, Frank Gotch 1, John W. Kusek 1, Nathan Levin 1, William Owen 1, Gerald Schulman 1, Robert Star 1, Robert Toto 1, Garabed Eknoyan 1, for the Hemodialysis Study Group

1

*Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio; {dagger}University of Illinois, School of Medicine, Chicago, Illinois; {ddagger}Division of Nephrology, University of California Davis, Sacramento, California; {sect}University of Alabama at Birmingham, Birmingham, Alabama; ||Department of Community Health, Wright State University, Boonshoft School of Medicine, Dayton, Ohio; ¶Renal Division, Washington University School of Medicine, St. Louis, Missouri; *University of California, School of Medicine, San Francisco, California; {dagger}{dagger}National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland; {ddagger}{ddagger}Renal Research Institute, Beth Israel Medical Center, New York, New York; {sect}{sect}University of Tennessee Health Science Center, Memphis, Tennessee; ||||Vanderbilt University Medical Center, Nashville, Tennessee; ¶¶University of Texas Southwestern Medical Center, Dallas, Texas; *Baylor College of Medicine, Houston, Texas


* To whom correspondence should be addressed. E-mail: tgreene{at}bio.ri.ccf.org.


   Abstract

In the intention-to-treat analysis of the Hemodialysis Study, all-cause mortality did not differ significantly between the high versus standard hemodialysis dose groups. The association of mortality with delivered dose within each of the two randomized treatment groups was examined, and implications for observational studies were considered. Time-dependent Cox regression was used to relate the relative risk (RR) for mortality to the running mean of the achieved equilibrated Kt/V (eKt/V) over the preceding 4 mo. eKt/V was categorized by quintiles within each dose group. Analyses were controlled for case-mix factors and baseline anthropometric volume. Within each randomized dose group, mortality was elevated markedly when achieved eKt/V was in the lowest quintile (RR, 1.93; 95% confidence interval [CI], 1.40 to 2.66; P < 0.0001 in the standard-dose group; RR, 2.04; 95% CI, 1.50 to 2.76; P < 0.0001 in the high-dose group; RR relative to the middle quintiles). The mortality rate in the lowest eKt/V quintile of the high-dose group was higher than in the full standard-dose group (RR, 1.59; 95% CI, 1.29 to 1.96; P < 0.0001). Each 0.1 eKt/V unit below the group median was associated with a 58% higher mortality in the standard-dose group (P < 0.001) and a 37% higher mortality in the high-dose group (P < 0.001). The magnitude of these dose-mortality effects was seven- to 12-fold higher than the upper limit of the 95% CI from the intention-to-treat analysis. The effects were attenuated in lagged analyses but did not disappear. When dialysis dose is targeted closely, as under the controlled conditions of the Hemodialysis Study, patients with the lowest achieved dose relative to their target dose experience markedly increased mortality, to a degree that is not compatible with a biologic effect of dose. The possibility of similar (albeit smaller) biases should be considered when analyzing observational data sets relating mortality to achieved dose of dialysis.




This article has been cited by other articles:


Home page
CLIN APPL THROMB HEMOSTHome page
J. Malyszko, J.S. Malyszko, P. Kozminski, K. Pawlak, and M. Mysliwiec
Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule
Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 338 - 345.
[Abstract] [PDF]


Home page
Nephrol Dial TransplantHome page
A. X. Garg, T. Greene, and N. W. Levin
A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 52 - 55.
[Full Text] [PDF]


Home page
JAMAHome page
D. W. Coyne
Epoetin Dosing and Dialysis Facility Ownership Reply
JAMA, August 22, 2007; 298(8): 862 - 863.
[Full Text] [PDF]


Home page
JAMAHome page
J. Himmelfarb
Chronic Kidney Disease and the Public Health: Gaps in Evidence From Interventional Trials
JAMA, June 20, 2007; 297(23): 2630 - 2633.
[Full Text] [PDF]


Home page
CJASNHome page
D. Van Wyck, K.-U. Eckardt, K. Uhlig, M. Rocco, and A. Levin
Appraisal of Evidence and Control of Bias in the Kidney Disease Outcomes Quality Initiative Guideline Development Process
Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 8 - 10.
[Full Text] [PDF]


Home page
CJASNHome page
H. Singh, J. Reed, S. Noble, J. L. Cangiano, D. B. Van Wyck, and for the United States Iron Sucrose (Venofer) Clini
Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized, Controlled Trial
Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 475 - 482.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP